

# STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (FG-130)

DEUTIVACAFTOR

PRONUNCIATION

due tiv'' a kaf' tor


THERAPEUTIC CLAIM

Treatment of cystic fibrosis

## CHEMICAL NAMES

1. 3-Quinolinecarboxamide, N-[2-(1,1-dimethylethyl)-4-[1,1-di(methyl-d3)ethyl-2,2,2-d3]-5-hydroxyphenyl]-1,4-dihydro-4-oxo-
2. *N*-{2-*tert*-butyl-5-hydroxy-4-[2-(<sup>2</sup>H<sub>3</sub>)methyl(1,1,1,3,3,3-<sup>2</sup>H<sub>6</sub>)propan-2-yl]phenyl}-4-oxo-1,4-dihydroquinoline-3-carboxamide

## STRUCTURAL FORMULA



MOLECULAR FORMULA

C<sub>24</sub>H<sub>19</sub><sup>2</sup>H<sub>9</sub>N<sub>2</sub>O<sub>3</sub>

MOLECULAR WEIGHT

401.6

TRADEMARK

None as yet

SPONSOR

Vertex Pharmaceuticals Inc.

CODE DESIGNATION

VX-561; CTP-656

CAS REGISTRY NUMBER

1413431-07-8

UNII

SHA6U5FJZL

WHO NUMBER

10704

SCS